CompletedNot Applicable

Visual Health Evaluation of New Designed Blue-blocking Glasses

China25 participantsStarted 2025-04-18

Plain-language summary

With the widespread use of electronic display devices, the potential hazards of blue light have become an important public health issue. The primary assessment and main outcome indicators of this experiment are the evaluation of the protective effects of a new type of filtering glasses on visual fatigue in the human eye. Secondary outcome indicators include tear film break-up time, accommodative facility, and subjective visual fatigue scores. Other outcome measurement indicators include visual function indicators such as accommodation and convergence. Baseline values of the above indicators were measured separately, and then specific numerical values of different indicators were collected after working with VDT devices while wearing the new type of filtering glasses or regular framed glasses. These values were statistically compared and analyzed with the baseline values. The study aims to assess the impact of the new type of filtering glasses on relieving visual fatigue and improving visual function.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * 1\. Adult population, regardless of gender 2. Refractive error is less than or equal to -2.5D and both eyes achieve corrected visual acuity of 0.8 or higher. 3. Normal intraocular pressure with no organic pathology. 4. No apparent symptoms of dry eye. 5. Willing to cooperate to complete all the tests. 6. Voluntarily signing the informed consent form. Exclusion Criteria: * 1: Individuals with strabismus and amblyopia exist. 2: Suffering from congenital eye conditions such as congenital cataracts or congenital retinal diseases. 3: Those who have undergone intraocular surgery (such as cataract removal, intraocular lens implantation, etc.). 4: Individuals with refractive media opacity (such as corneal lesions, lens opacity, etc.). 5: Abnormal intraocular pressure (IOP) (IOP \< 10 mmHg or IOP \> 21 mmHg, or a bilateral IOP difference of ≥5 mmHg). 6: Abnormal intraocular pressure (IOP) (IOP \< 10 mmHg or IOP \> 21 mmHg, or a bilateral IOP difference of ≥5 mmHg). 7: Only one eye meets the inclusion criteria. 8: Active corneal infections such as bacterial, fungal, viral, or other acute or chronic anterior segment inflammations. 9: Currently using medications that may lead to dry eye or affect vision and corneal curvature. 10: Other ocular conditions, such as dacryocystitis, eyelid disorders and abnormalities, abnormal intraocular pressure, and glaucoma. 11: Unable to undergo regular eye examinations.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1This trial looked at blue-blocking glasses using something called 'critical flicker fusion frequency' — can you explain what that measurement actually tells us about eye health or visual performance, and whether it's something that matters for my specific situation?
2Since this trial is already completed, is the results data available yet, and if so, what did it actually show about whether these blue-blocking glasses made a meaningful difference in visual health?
3Blue-blocking glasses are widely sold over the counter, so how does what was studied in this trial compare to what I might already be using or could buy on my own — is there a clinically important difference?
4Are there any established guidelines or existing evidence you'd point me to about blue-blocking glasses before I consider relying on them for my eye health, given that this was a non-drug, device-type study with no standard phase classification?
5If someone in my position is concerned about screen time and eye strain, would you recommend blue-blocking glasses based on current evidence, or are there other strategies that have stronger support?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Critical flicker fusion frequency

Timeframe: Participants underwent two randomized experimental conditions. For each condition, CFF test was administered at baseline (pre-experiment), post-task on day 1, and post-task on day 7, totaling six completions per participant.

Trial details

NCT IDNCT06984783

SponsorBeijing Tongren Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-06-20

View on ClinicalTrials.gov More Blue-blocking Glasses trials